Linked CIViC Profile: ALK FUSION
Evidence Level Distribution
Level B: 1Level C: 14Level D: 21
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | ALK Inhibitor TAE684 | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ceritinib | 4 |
| C | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Alectinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ceritinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Lorlatinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Lorlatinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ceritinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Crizotinib | 4 |
| C | Predictive | Does Not Support | Sensitivity/Response | Mucosal Melanoma | Entrectinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Ceritinib | 4 |
| D | Predictive | Supports | Resistance | Inflammatory Myofibroblastic Tumor | Crizotinib | 3 |
| D | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Crizotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Alectinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Crizotinib | 3 |
| D | Predictive | Supports | Resistance | Neuroblastoma | ALK Inhibitor TAE684 | 3 |
| D | Predictive | Supports | Resistance | Neuroblastoma | Crizotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Crizotinib | 3 |
| C | Predictive | Does Not Support | Sensitivity/Response | Neuroblastoma | Crizotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | ALK Inhibitor TAE684 | 3 |
| D | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Crizotinib | 3 |